Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 14/20 | 0.91 |
| ▸ | JAK1 | P23458 | 5/20 | 0.91 |
| ▸ | JAK3 | P52333 | 5/20 | 0.91 |
| ▸ | JAK2 | O60674 | 4/20 | 0.91 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.91 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.91 |
| ▸ | PLK4 | O00444 | 2/20 | 0.91 |
| ▸ | AURKA | O14965 | 2/20 | 0.91 |
| ▸ | STK16 | O75716 | 2/20 | 0.91 |
| ▸ | RET | P07949 | 2/20 | 0.91 |
| ▸ | FLT3 | P36888 | 2/20 | 0.91 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.91 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.91 |
| ▸ | MST1R | Q04912 | 2/20 | 0.91 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.91 |
| ▸ | TNK1 | Q13470 | 2/20 | 0.91 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.91 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.91 |
| ▸ | ADCK1 | Q86TW2 | 2/20 | 0.91 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12903946 | 0.95 | SYK (0.82) | SYKJAK1JAK3JAK2ADORA3 | |
| SCHEMBL12903953 | 0.95 | SYK (0.82) | SYKJAK1JAK3JAK2ADORA3 | |
| R-406 SCHEMBL29358236 | 0.95 | SYK (1.00) | SYKJAK1JAK3JAK2ADORA3 | |
| R-406 SCHEMBL1200144 | 0.95 | SYK (1.00) | SYKJAK1JAK3JAK2ADORA3 | |
| SCHEMBL12903945 | 0.93 | SYK (0.78) | SYKJAK1JAK3JAK2ADORA3 | |
| SCHEMBL12903959 | 0.92 | SYK (0.77) | SYKJAK1JAK3JAK2ADORA3 | |
| SCHEMBL11937326 | 0.92 | SYK (0.87) | SYKJAK1JAK3JAK2ADORA3 | |
| R-406 SCHEMBL12903997 | 0.91 | SYK (0.92) | SYKJAK1JAK3JAK2ADORA3 | |
| SCHEMBL1383686 | 0.91 | SYK (0.89) | SYKJAK1JAK3JAK2ADORA3 | |
| R-406 SCHEMBL12903982 | 0.90 | SYK (0.91) | SYKJAK1JAK3JAK2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-9737554-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9532998-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160367575-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160136191-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-19 | — | — | US | disclosed |
| US-9283238-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9266912-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150133404-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | US | disclosed |
| US-8912170-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140357598-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20120108810-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8163902-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-7989448-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110144059-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| US-7962290-B1 | Identification of pharmacophores from co-crystals of spleen tyrosine kinase (SYK) and SYK ligands | RIGEL PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | RIGEL PHARMACEUTICALS, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| US-7563892-B1 | Prodrugs of 2,4 pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7538108-B2 | Prodrugs of 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | RIGEL PHARMACEUTICALS, INC. | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357598-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885JAK1 3777/4885JAK3 3380/4885 |
| US-20160367575-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2198/4885JAK1 3777/4885JAK3 3546/4885 |
| US-20160136191-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885JAK1 3777/4885JAK3 3380/4885 |
| US-20150133404-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2198/4885JAK1 3777/4885JAK3 3546/4885 |
| US-20110015155-A1 | Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses | DPYD, DUT, TYMP | SYK 2772/4885JAK1 3139/4885JAK3 2271/4885 |
| US-20180153912-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2198/4885JAK1 3777/4885JAK3 3546/4885 |
| US-20110144059-A1 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | DPYD, TYMP, DCTD | SYK 2198/4885JAK1 3777/4885JAK3 3546/4885 |
| US-20110319613-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885JAK1 3777/4885JAK3 3380/4885 |
| US-20090124580-A1 | Autoimmune diseases; water solubility of prodrug can be tailored to improve bioavailability using substution at amine groups; inhibitors of degranulation of immune cells; inhibit/activate Fc receptor signaling cascades | FCGR3B, FCER2, FCGR1A | SYK 8/4885JAK1 472/4885JAK3 872/4885 |
| US-20120108810-A1 | Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses | DPYD, TYMP, DCTD | SYK 2055/4885JAK1 3777/4885JAK3 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.